GLP-1受体激动剂作用机制及皮肤健康潜在通路
本文综述GLP-1受体激动剂及双重GLP-1/GIP受体激动剂的发展历史与作用机制,强调其广泛细胞分布与生理作用。除降糖和β细胞功能外,这类药物具有免疫调节效应,可能改善银屑病、化脓性汗腺炎、伤口愈合及伤害性信号传导,提示皮肤科应用潜力。
要点
- GLP-1类药物具免疫调节作用,可减弱促炎细胞因子信号并促进抗炎通路。
- 新兴证据提示可能改善银屑病、化脓性汗腺炎及伤口愈合。
- 皮肤科应用需进一步研究受体特异性机制并优化整合。
核心结论
- GLP-1类药物除代谢调节外具免疫调节效应,可能对银屑病、化脓性汗腺炎、伤口愈合及伤害性信号传导有改善作用,拓展了治疗范围。
研究设计与样本
- 本文为综述,概述GLP-1受体激动剂及双重GLP-1/GIP受体激动剂的发展历史与作用机制。
主要发现
- GLP-1类药物具免疫调节作用,减弱促炎细胞因子信号并促进抗炎通路。
- 新兴证据可能支持其在皮肤科的相关性,包括改善银屑病和化脓性汗腺炎、增强伤口愈合及调节伤害性信号传导。
临床怎么用
- 提示皮肤科医生可关注GLP-1类药物在银屑病、化脓性汗腺炎、伤口愈合等方面的潜在获益,但需进一步研究以优化临床整合。
局限性
- 需持续研究以阐明皮肤生物学中的受体特异性机制,并优化这些疗法在皮肤科实践中的整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of obesity and type 2 diabetes mellitus (T2DM) continues to rise in the United States (U.S.) and worldwide, contributing to substantial morbidity and mortality through metabolic dysfunction and systemic inflammation. Glucagon-like peptide-1(GLP-1)-based therapies, originally developed for glycemic control, have since demonstrated significant weight loss benefits and multiple effects across multiple organ systems. This review provides an overview of the historical development and mechanistic underpinnings of GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, with emphasis on their broad cellular distribution and physiologic actions. Beyond their well-established roles in glucose regulation and β-cell function, GLP-1-based agents exert immunomodulatory effects, attenuating pro-inflammatory cytokine signaling while promoting anti-inflammatory pathways. Emerging evidence may support their relevance in dermatology, including improvement in psoriasis and hidradenitis suppurativa (HS), enhanced wound healing, and modulation of nociceptive signaling. These findings underscore the expanding therapeutic scope of GLP-1-based agents, suggesting potential utility in both systemic metabolic disease and dermatologic conditions. Continued investigation is warranted to clarify receptor-specific mechanisms in skin biology and to optimize integration of these therapies into dermatologic practice.
引用
- Narla S, Narla RR, Corbett JA, et al. JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health. J Am Acad Dermatol. 2026. PMID: 41707707. doi:10.1016/j.jaad.2026.01.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。